Since 1994, four cases of epidermal nevus with epidermolytic hyperkeratosis (EH) caused by K10 gene mutations have been reported, although no K1 gene mutation has yet been reported. We detected a K1 gene (KRT1) mutation in epidermal nevus with EH in a 10-year-old Japanese male. The patient showed well-demarcated verrucous, hyperkeratotic plaques mainly on the trunk, covering 15 % of the entire body surface. No hyperkeratosis was seen on the palms or soles. He had no family history of skin disorders. His lesional skin showed typical granular degeneration and, ultrastructurally, clumped keratin filaments were observed in the upper epidermis. Direct sequence analysis of genomic DNA extracted from lesional skin revealed a heterozygous 5' donor splice site mutation c.591+2T>A in KRT1. This mutation was not detected in genomic DNA samples from patient's peripheral blood leukocytes or those of other family members. The identical splice mutation was previously reported in a family with palmoplantar keratoderma and mild ichthyosis, and was demonstrated to result in a 22 amino acid deletion p.Val175_Lys196del in the H1 and 1A domains of K1. The present patient is the first reported case of epidermal nevus associated with EH caused by a K1 gene mutation in a mosaic pattern.
INTRODUCTION
Epidermal nevi are skin hamartomatous lesions comprised of keratinocytes. Their clinical features include circumscribed verrucous lesions of any size, single or multiple in nature, and they can occur at any site, frequently following Blaschko's lines. Epidermal nevi are thought to reflect a genetic mosaicism and, it has been often hypothesized that epidermal nevi with epidermolytic hyperkeratosis (EH) reflect differentiation specific, suprabasal keratin gene mutations. The term "EH" in this case means pathological changes seen in bullous congenital ichthyosiform erythroderma (BCIE), a keratin 1 (K1)/keratin 10 (K10) disease, although EH is a histological feature of more than one disease.
Indeed, K10 gene mutations were reported in four cases of epidermal nevi with EH (Paller et al., 1994; Moss et al., 1995) , although no K1 gene mutation has yet been reported. A mosaic mutation in the V1 domain of keratin 16 was reported to underlie unilateral palmoplantar verrucous nevus with vacuolar degeneration of keratinocytes in the upper epidermis (Terrinoni et al., 2000) . A diverse range of subtly different phenotypes including classical BCIE has been described with mutations in K1 (reviewed in Lane and McLean, 2004) . Splice site mutations affecting the K1 peptide 1A or 2B domain caused epidermolytic palmoplantar keratoderma (PPK) (reviewed in Terron-Kwiatkowski et al., 2002) . Now a total of 47 different mutations have been reported in K1 (The Human Intermediate Filament Database).
Here we report that a splice site mutation in the K1 gene, previously reported in a case of PPK and mild ichthyosis, was associated with the epidermal nevus with EH disease phentoype. As far as we know, the 3 present case is the first reported patient of epidermal nevus with EH associated with a K1 gene mutation.
RESULTS

Clinical features
A 10-year-old Japanese male showed well-demarcated verrucous, hyperkeratotic plaques mainly on the trunk, covering 15 % of his entire body surface. They distributed following the Blaschko's lines (Figure 1 ).
No hyperkeratosis was seen on the palms and soles. The other family members including his parents and elder brother had neither BCIE nor epidermal nevus. genes. The mutation was not found in 100 normal, unrelated Japanese alleles (50 healthy unrelated Japanese individuals) by sequence analysis, and was unlikely to be a polymorphism (data not shown).
By mutant allele specific amplification analysis (Hasegawa et al., 1995; Xu et al., 2003) , a 102 bp fragment derived from the mutant allele was amplified from the genomic DNA sample extracted from the lesional skin ( Figure 2b ). The 102 bp fragment was sequenced and it was confirmed that the fragment was derived from the targeted region of K1 gene, KRT1. The mutant allele specific amplification showed no PCR product bands from the peripheral blood cell DNA samples from the patient, any other family members or controls.
K1 expression was weak and keratin 2e (K2e) expression was upregulated in the epidermal nevus lesion
Immunofluorescence studies revealed that K1 and K10 were present in the lesional epidermal suprabasal layers, although K1 expression was weaker than that in the normal control skin ( Figure S1a 
DISCUSSION
All the reported causative mutations underlying epidermal nevus with EH affected the K10 gene (Paller et al., 1994; Moss et al., 1995) . As far as we know, the present case is the first reported case of epidermal nevus with EH caused by a K1 gene mutation.
K2e expression increased in the lesional epidermis of the present case.
Although we do not have any direct evidence, K2e expression might be upregulated compensatively in the epidermis with disrupted keratin network. Indeed, increased K2e expression was also observed in the lesional epidermis with disturbed keratin network of ichthyosis bullosa of Siemens patients (Akiyama et al., 2005) .
In our case, the causative K1 mutation was detected only in the lesional skin, but not in the peripheral blood cells, as previously reported in K10 mutations in epidermal nevus with EH (Paller et al., 1994; Moss et al., 1995) . Our findings further support that the mutation detection of K1 as well as K10 in epidermal nevus can be reliably performed only from direct examination of lesional skin, not from analysis of other tissue or peripheral blood cells.
As epidermal nevus is a disease caused by somatic mosaicism, widespread 6 skin lesions increase the risk of germ-line transmission (Paller et al., 1994) .
In case causative K1 or K10 mutations are transmitted in germ-line, a half of the children from patients with epidermal nevus with EH are expected to be affected with ichthyosis on the whole body. Mutation analysis using a patient's sperm gives us information on germ-line transmission (Zlotogora, 1998; Rantamaki et al., 1999) . If the germ-line transmission is confirmed, prenatal genetic screening may be applied for the offspring of the patient as previously reported in the prenatal diagnosis of BCIE by molecular analysis (Rothnagel et al., 1994; Tsuji-Abe et al., 2004) .
The K1 gene mutation detected in the present case was a splice donor site mutation c.591+2T>A. According to Splice Site Prediction by Neural Network software (http://www.fruitfly.org/seq_tools/splice.html) (Tal et al., 2005; Wessagowit et al., 2005; Wessagowit et al., 2006) , a consequence of this mutation is predicted with the highest probability, we can expect a splice variant with an upstream cryptic splice donor site resulting in a 66 bp deletion (22 amino acid deletion; p.Val175-Lys196del). The second highest probability, an alternative splice pattern activating a cryptic donor site 22 bp downstream of the mutation with the subsequent insertion of 8 amino acids into the 1A rod domain was predicted. Indeed, in a patient with PPK with the same K1 gene mutation as in the present case, mRNA expression analysis by in vitro splicing assay clearly indicated that the splice site mutation c.591+2T>A results in a partial deletion of the H1 and 1A domains of K1 (p.Val175_Lys196del) (Terron-Kwiatkowski et al., 2002) , as predicted by the highest probability using the software model.
Concerning reported mutations in the adjacent nucleotide as our mutation 7 in the K1 gene, i.e. splice donor site mutations c.591+1T>A and c.591+3T>A were reported to lead to the same 22 amino acid deletions (Vitanen et al., 2003; Tal et al., 2005) . Thus, we may expect an identical 22 amino acid deletion p.Val175_Lys196del in K1 peptides as a consequence of the KRT1 mutation c.591+2T>A in lesional keratinocytes from the present patient.
Interestingly, the KRT1 mutation that had been reported to cause PPK (Terron-Kwiatkowski et al., 2002) led to an epidermal nevus with EH phenotype distributed on the trunk and the extremities in our case. In the previous PPK patient with an identical mutation, only mild hyperkeratosis was found over limited body areas and it was speculated that loss of the protein motif in the helix boundary that is essential for the interaction of keratin filaments (Steinert et al., 1993) have a less disruptive effect on normal keratin filament assembly (Terron-Kwiatkowski et al., 2002) . A similar mechanism can be expected in deletions at either end of the K1 rod domain. Indeed, a splice site mutation in K1 that leads to the insertion of 18 amino acids into the 2B domain led to a mild epidermolytic PPK phenotype (reviewed in Terron-Kwiatkowski et al., 2002) . However, in our case, the mosaicism of the mutation showed an epidermal nevus phenotype even on the trunk and the extremities. The precise mechanism of how identical splice site mutations can result in a different severity of the lesions on the trunk remains unclear.
Until the present report, all the reported mosaic mutations causing 8 epidermal nevus with EH had been due to K10 mutations that would have resulted in BCIE if every cell in the body were affected (Paller et al., 1994; Moss et al., 1995) . In conclusion, the present case clearly indicated that K1 mutations with genetic mosaicism also cause epidermal nevus with EH. The present K1 mosaicism might have led to PPK with mild hyperkeratotic lesions if all the epidermal cells were affected over the entire body surface (Terron-Kwitkowski et al., 2002) .
MATERIALS AND METHODS
Mutation detection
Mutation analysis was performed using genomic DNA extracted from the lesional epidermal nevus skin and peripheral blood leukocytes from the patient. In the other family members and normal controls, genomic DNA isolated from peripheral blood leukocytes was used for the analysis. Briefly, genomic DNA samples were subjected to PCR amplification, followed by direct automated sequencing using an ABI PRISM 3100 genetic analyzer (ABI Advanced Biotechnologies, Columbia, MD, U.S.A.). The oligonucleotide primers were designed using the website program (primer3_www.cgi v 0.2). The primers used for amplification of exon 1 were as follows; forward, gtggacgtggtagtggcttt; reverse, ctttaggtcgaccaccaacc. The entire coding region including the intron/exon boundaries for both forward and reverse strands were sequenced. For normal controls, 50 healthy unrelated Japanese individuals (100 normal alleles) were studied.
Mutant allele specific amplification analysis Long and accurate (LA)-PCR was done using primers, forward primer ex1F1; aggaggtgggagatttt and a reverse primer ex2R; catgctgcttcatgatcttagc. For the verification of the mutation, using LA-PCR products as a template, mutant allele specific amplification analysis was performed with mutant allele specific primers carrying the substitution of two bases at the 3'-end (Linard et al., 2002; Sapio et al., 2006) , as follows; forward, gcctccttcattgacaagaa; reverse, ttcaaacctgcgtgtgttttgactgcaccgatccc. PCR conditions were as follows; 94℃ for 5 min after (hot-start procedure) and then 94℃ for 1 min, 56℃ for 1 min, 72℃ for 1 min during 35 cycles, followed by 72℃ for 7 min. Only the 102 bp fragment derived from the mutant allele was amplified with these primers and the PCR condition.
Ultrastructural observations Epidermal nevus on the trunk was biopsied for morphological observation. Skin biopsy samples were fixed in 2% glutaraldehyde solution, post-fixed in 1% OsO4, dehydrated, and embedded in Epon 812. The samples were sectioned at 1 µm thickness for light microscopy and thin sectioned for electron microscopy (70 nm thick). The thin sections were stained with uranyl acetate and lead citrate and examined in a transmission electron microscope.
Antibodies Polyclonal anti-K1 antiserum (DAKO, Glostrup, Denmark), anti-K2e antibody (Progen Biotechnick, Heidelberg, Germany) and anti-K10 antiserum (Novocastra, New Castle upon Tyne, England) were used in the present study.
Immunofluorescent labeling Immunofluorescent labeling was performed as described previously (Akiyama et al., 2000) . Briefly, 6-µm-thick sections of freshly frozen patient's skin was cut using a cryostat. The sections were incubated in primary antibody solution for 30 min at 37˚C. Antibody dilutions were as follows; 1/10 for anti-K1 antiserum, 1/50 for anti-K2e antibody and 1/100 for anti-K10 antibody. The sections were then incubated in fluorescein isothiocyanate-conjugated to rabbit anti-mouse immunoglobulins and FITC-conjugated goat anti-mouse immunoglobulins diluted 1:100 (DAKO, Glostrup, Denmark) for 30 min at 37℃. The sections were extensively washed with phosphate-buffered saline between incubations. The stained sections were then mounted with a cover slip and observed using a confocal laser scanning microscope.
The medical ethical committee at Hokkaido University and Hokkaido Cancer Institute approved all described studies. The study was conducted according to the Declaration of Helsinki Principles.
Participants gave their written, informed consent. 
